RxDoctor Payments Data

Alden Glidden, MD

Family Medicine · Klamath Falls, ORNPI 1386691897

Payments from drug & device makers

$851in general payments, 2019–2025

Across 33 payments — averaging $25.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$290
  • AstraZeneca$145
  • Medtronic$126
  • AbbVie$118
  • Lilly USA, LLC$74
  • Pfizer$35
  • plus $64 from 4 others

What the payments were for

  • Food & beverage$79994%
  • Education$526%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$851 in reported general payments places this provider in the 85th percentile of 1,221 family medicine providers in Oregon.

See all family medicine providers in Oregon

Medicare billing

Part B allowed, 2024
$68,402
Medicare patients
389
Services billed
905

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban99$112,503
MounjaroTirzepatide108$107,884
TrulicityDulaglutide52$79,735
OzempicSemaglutide54$74,189
JardianceEmpagliflozin55$73,499
XareltoRivaroxaban22$25,186
FarxigaDapagliflozin Propanediol20$20,534
Breo ElliptaFluticasone/Vilanterol13$15,344
Semglee (Yfgn) PenInsulin Glargine-Yfgn24$9,724
MyrbetriqMirabegron16$8,340
Atorvastatin Calcium475$7,808
Rosuvastatin Calcium345$6,887
Gabapentin291$6,631
Tamsulosin Hcl226$6,597
Stiolto RespimatTiotropium Br/Olodaterol Hcl13$6,020

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$74$187,619160 claims
PfizerEliquis$35$112,50399 claims
Johnson & JohnsonXarelto$290$25,18622 claims
GSKBreo Ellipta, Anoro Ellipta$14$21,25325 claims
AstraZenecaFarxiga$145$20,53420 claims
Astellas Pharma US IncMyrbetriq$20$8,34016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,221 family medicine providers in Oregon.

Other family medicine in Klamath Falls

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →